682 related articles for article (PubMed ID: 26340986)
21. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
22. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.
Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ
J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042
[TBL] [Abstract][Full Text] [Related]
23. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
25. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
Hacıoğlu S; Sarı I; Doğu MH; Keskin A
Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
[TBL] [Abstract][Full Text] [Related]
26. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.
Min YJ; Kim SW; Suh C; Park J; Kim HJ; Kim JG; Kim TW; Lee JH; Kim SB; Lee KH; Lee JS; Kim WK; Kim SH
J Korean Med Sci; 2000 Feb; 15(1):49-52. PubMed ID: 10719808
[TBL] [Abstract][Full Text] [Related]
27. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
28. Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
Jang JE; Cheong JW; Kim SJ; Cho H; Suh C; Lee H; Eom HS; Yhim HY; Lee WS; Min CK; Lee JH; Park JS; Kim JS
Leuk Lymphoma; 2016; 57(6):1389-97. PubMed ID: 26428939
[TBL] [Abstract][Full Text] [Related]
29. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone.
Cremer FW; Kiel K; Wallmeier M; Haas R; Goldschmidt H; Moos M
Exp Hematol; 1998 Sep; 26(10):969-75. PubMed ID: 9728932
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
31. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
Int J Hematol; 2018 May; 107(5):559-567. PubMed ID: 29388164
[TBL] [Abstract][Full Text] [Related]
32. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.
Winkelmann N; Desole M; Hilgendorf I; Ernst T; Sayer HG; Kunert C; Mügge LO; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2603-2610. PubMed ID: 27640002
[TBL] [Abstract][Full Text] [Related]
34. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan F; Kochuparambil ST; Falconer DE; Cumpston A; Leadmon S; Watkins K; Deremer D; Jillella A; Craig M; Hamadani M
Bone Marrow Transplant; 2013 Oct; 48(10):1279-84. PubMed ID: 23584435
[TBL] [Abstract][Full Text] [Related]
35. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
36. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
37. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
[TBL] [Abstract][Full Text] [Related]
38. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
[TBL] [Abstract][Full Text] [Related]
39. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
40. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]